Ubr1 Inhibitors

UBR1 inhibitors encompass a variety of chemical compounds that do not directly target the UBR1 protein but interfere with the ubiquitin-proteasome system where UBR1 operates. These inhibitors can be classified based on their target within the ubiquitination pathway. For instance, proteasome inhibitors such as MG132, Bortezomib, Lactacystin, Clasto-lactacystin β-lactone, Epoxomicin, Withaferin A, and Celastrol disrupt the final step of protein degradation, causing an accumulation of ubiquitinated proteins, which indirectly affects the turnover of substrates recognized by UBR1. These compounds range from peptide aldehydes to natural products and synthetic peptides, each with a unique mechanism of action for inhibiting proteasomal activity.

UBR1 pathway modulators includes compounds that target upstream ubiquitination processes. MLN4924 inhibits the NEDD8-activating enzyme, which is essential for activating E3 ubiquitin ligases like UBR1, while PYR-41 blocks the ubiquitin-activating enzyme E1, a critical enzyme that initiates the ubiquitination cascade. IU1, by inhibiting the deubiquitinating enzyme USP14, alters the dynamics of protein degradation mediated by the proteasome, and consequently, the role of UBR1 in targeting proteins for degradation. Thalidomide, although not directly interacting with UBR1, can modulate the stability of certain proteins, which may overlap with UBR1 substrates. Lastly, compounds like EerI trigger ER stress and a subsequent accumulation of misfolded proteins, potentially overloading the UBR1-dependent degradation pathway.